March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Reciprocal Activities of Two Type Dopamine Receptors Determine the Myopia Development
Author Affiliations & Notes
  • Li Qin Jiang
    Eye Hosp, Wenzhou Med College, Wenzhou Zhejiang, China
  • Keli Long
    Eye Hosp, Wenzhou Med College, Wenzhou Zhejiang, China
  • Xiangtian Zhou
    Eye Hosp, Wenzhou Med College, Wenzhou Zhejiang, China
  • Jia Qu
    Eye Hosp, Wenzhou Med College, Wenzhou Zhejiang, China
  • Footnotes
    Commercial Relationships  Li Qin Jiang, None; Keli Long, None; Xiangtian Zhou, None; Jia Qu, None
  • Footnotes
    Support  National Basic Research Program of China (973 project; 2011CB504602)
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3437. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Li Qin Jiang, Keli Long, Xiangtian Zhou, Jia Qu; Reciprocal Activities of Two Type Dopamine Receptors Determine the Myopia Development. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3437.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Dopaminergic activity has been known to involve emmetropization, a key process of the refractive development. However, the mechanism by which it regulates myopia development has not been elucidated. This study was to explore the reciprocal role of dopamine receptors (D1 that activates cAMP, and D2 that inhibits cAMP) in regulating myopia development in albino guinea pigs, which spontaneously develop myopia with reduced dopamine activity.

Methods: : Albino guinea pigs were treated for 4 weeks in 2-6 weeks after birth with apomorphine (APO), an unselective dopamine receptor agonist, by semiretrobulbar injection to right eyes daily, with left eyes used as untreated controls. Six dosages of APO (7.5, 25, 75, 250, 750, and 2500 ng) were tested. Dopamine receptor D1 selective agonist SKF38393, and D2 selective agonist Quinpirole, both in 3 doses (10, 100, and 1000 ng), were also investigated, with untreated or vehicle-treated animals as controls. 15 animals were used per group for each dose. Refraction (RE) and axial length (AL) were measured at 2, 4, and 6 weeks by eccentric infrared photoretinoscopy and A-scan ultrasound, respectively. The difference of RE and AL between treated and untreated eyes was calculated at 6-week old. The negative value of RE difference and positive AL difference indicate myopia progress, and vice versa.

Results: : Albino guinea pigs showed significant myopia progress, from RE at -5.96±0.48D in 2 weeks, to -7.52±0.79D at 6 weeks, similar to the vehicle group. APO showed biphasic effects on RE and axial eye growth: a low dose (25ng) promoted myopia development with RE at -8.82±0.67D in 6 weeks, while a high dose (250ng) prevented it (RE: -5.73±0.68D at 6-week). The difference between two eyes in APO and vehicle groups were: RE: -1.16±0.33D vs. 0.09±0.25D (p<0.01), and AL: 0.04±0.01mm vs. 0.00±0.01mm (p=0.135) in APO 25ng group; while RE was +1.72±0.61D vs. 0.09±0.25D (p<0.05), and AL was -0.10±0.04mm vs. 0.00±0.01mm (p<0.05) in 250ng group. Interestingly, D1 receptor agonist SKF38393 at 100ng had a significant inhibitory effect on myopia development, with the RE difference +1.00±0.52D vs. 0.00±0.53D (p<0.05); and the AL difference is -0.06±0.03mm vs. 0.00±0.04mm (p<0.05). D2 receptor agonist quinpirole appeared to promoted myopia, but there was no statistic significance.

Conclusions: : Our findings demonstrated that dopaminergic system regulates myopia development through the reciprocal activities of two type dopamine receptors in albino guinea pigs: D1 receptor activity inhibits, while D2 receptor agonist promotes myopia, which may have preventive or therapeutic potential in myopia development, especially in youth myopia.<!--EndFragment-->

Keywords: myopia • dopamine • receptors: pharmacology/physiology 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.